Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 10/20 | 0.78 |
| ▸ | MAPK9 | P45984 | 10/20 | 0.78 |
| ▸ | MAPK10 | P53779 | 9/20 | 0.78 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.78 |
| ▸ | CDK2 | P24941 | 7/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.78 |
| ▸ | CDK1 | P06493 | 1/20 | 0.70 |
| ▸ | CDK4 | P11802 | 1/20 | 0.70 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.70 |
| ▸ | CCND1 | P24385 | 1/20 | 0.70 |
| ▸ | MKNK1 | Q9BUB5 | 8/20 | 0.52 |
| ▸ | MKNK2 | Q9HBH9 | 7/20 | 0.52 |
| ▸ | IDH1 | O75874 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4004010 | 1.00 | MAPK8 (0.78) | MAPK8MAPK9MAPK10CCNE1CDK2 | |
| SCHEMBL473602 | 0.91 | MAPK8 (0.80) | MAPK8MAPK9MAPK10CCNE1CDK2 | |
| SCHEMBL4000544 | 0.91 | MAPK8 (0.76) | MAPK8MAPK9MAPK10CCNE1CDK2 | |
| SCHEMBL473603 | 0.91 | MAPK8 (0.80) | MAPK8MAPK9MAPK10CCNE1CDK2 | |
| SCHEMBL4000541 | 0.91 | MAPK8 (0.76) | MAPK8MAPK9MAPK10CCNE1CDK2 | |
| SCHEMBL473583 | 0.89 | MAPK8 (0.77) | MAPK8MAPK9MAPK10CCNE1CDK2 | |
| SCHEMBL473585 | 0.89 | MAPK8 (0.77) | MAPK8MAPK9MAPK10CCNE1CDK2 | |
| SCHEMBL473566 | 0.88 | MAPK8 (0.85) | MAPK8MAPK9MAPK10CCNE1CDK2 | |
| SCHEMBL473393 | 0.88 | MAPK8 (1.00) | MAPK8MAPK9MAPK10CCNE1CDK2 | |
| SCHEMBL473392 | 0.88 | MAPK8 (1.00) | MAPK8MAPK9MAPK10CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962622-B2 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2066319-B1 | BENZOTRIAZOLE KINASE MODULATORS | HOFFMANN LA ROCHE (CH) | 2012-02-01 | — | — | EP | disclosed |
| EP-2066319-A1 | BENZOTRIAZOLE KINASE MODULATORS | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| US-20080103142-A1 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC | 2008-05-01 | — | — | US | disclosed |
| WO-2008028860-A1 | BENZOTRIAZOLE KINASE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103142-A1 | Benzotriazole kinase modulators | CDK1, CDK3, MAPK1 | MAPK8 61/4885MAPK9 65/4885MAPK10 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.